A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
- Conditions
- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
- Interventions
- Other: Placebo
- Registration Number
- NCT05063162
- Lead Sponsor
- UCB Biopharma SRL
- Brief Summary
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 104
- Participant must be ≥18 to ≤89 years of age, at the time of signing the informed consent
- Confirmed diagnosis of MOG-AD consistent with published diagnostic criteria for MOG-AD
- Participant has history of relapsing MOG-AD with at least 1 documented relapse over the last 12 months and a documented positive serum MOG Ab test using a cell-based assay (CBA) within 6 months prior to randomization
- Participant must be clinically stable at the time of the Screening Visit and during the Screening Period
- Participant has been diagnosed with a neurological autoimmune disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant
- Participant has a clinically important active infection (including unresolved or not adequately treated infection) as assessed by the investigator, including participants with a serious infection within 6 weeks prior to the first dose of the investigational medicinal product (IMP)
- Participant has a current or medical history of primary immunodeficiency
- Participant tests positive for aquaporin-4 antibodies at Screening
- Participant has a serum total IgG level ≤ 5.5g/L
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Arm Placebo Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding. Rozanolixizumab Arm Rozanolixizumab Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints.
- Primary Outcome Measures
Name Time Method For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment Period Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks) The TTFR (days) will be defined as the interval between the date of randomization and the first date of the objective relapse.
During the Double Blind (DB) Treatment Period (Part A); EDB/EWD = End of Double-Blind/Early Withdrawal VisitFor Part B: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment Period OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52) An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs leading to discontinuation of the study are reported.
During Part B.For Part B: Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment Period OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52) An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
Open-Label Extension (OLE) Treatment Period (Part B); EOS/EWD = End of Study/Early Withdrawal Visit.
- Secondary Outcome Measures
Name Time Method For Part A: Number of MOG-AD related inpatient hospitalizations during the DB Treatment Period Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks) The total number of MOG-AD related hospitalizations from Baseline through EDB/EWD Visit.
During Part A.For Part B: Independently centrally adjudicated annualized relapse rate (ARR) during the DB and OLE Treatment Period Baseline (Week 1) to EOS/EWD Visit (up to OLE Week 52) An ARR will be calculated for each participant prior to randomization into the Double-Blind Treatment Period (based on available historical data), and 2 ARRs after randomization to study treatment: first for relapses occurring during the Double-Blind Treatment Period and the second for relapses occurring during the OLE Treatment Period. The relapse episodes for each participant will be recorded throughout the entire study.
For Part A: Incidence of treatment-emergent adverse events (TEAEs) during the DB Treatment Period Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks) An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
During Part A.For Part A: Change from Baseline in Low-Contrast Monocular Visual Acuity (Worst Affected Eye) measured by low-contrast Landolt C Broken Rings Chart at the EDB/EWD Visit From Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks) Visual acuity is a measurement of the capacity for visual discrimination of fine details. Visual acuity tests are used to determine the smallest characters that can be read on a standardized chart. The Landolt C Broken Ring Chart uses standardized incomplete rings or "C", which are positioned in any direction in the chart (up, down, left, right, and 45 degree positions in between). The participant has to be able to indicate where the break of the "C" is located, by describing the position or by giving gesture.
During Part A.For Part A: Disability as assessed by Expanded Disability Status Scale (EDSS) scores at the EDB/EWD Visit (with confirmation at 3 months) Baseline (Week 1), EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks) The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments with half steps from 1.0 to 9.5. The higher the value the higher is the level of impairment and disability.
During Part A.
Trial Locations
- Locations (77)
Mog001 20226
🇰🇷Goyang-si, Korea, Republic of
Mog001 20104
🇰🇷Seoul, Korea, Republic of
Mog001 50485
🇲🇽Ciudad de Mexico, Mexico
Mog001 50486
🇲🇽Culiacán, Mexico
Mog001 40485
🇵🇹Coimbra, Portugal
Mog001 40669
🇵🇹Porto, Portugal
Mog001 40267
🇪🇸Barcelona, Spain
Mog001 40100
🇪🇸Madrid, Spain
Mog001 40161
🇪🇸Madrid, Spain
Mog001 40350
🇪🇸Murcia, Spain
Mog001 40341
🇪🇸Málaga, Spain
Mog001 40049
🇪🇸Sevilla, Spain
Mog001 40660
🇸🇪Gothenburg, Sweden
Mog001 40663
🇸🇪Huddinge, Sweden
Mog001 40723
🇨🇭Basel, Switzerland
Mog001 40337
🇨🇭Bern, Switzerland
Mog001 40630
🇨🇭Zurich, Switzerland
Mog001 20096
🇨🇳Changhua City, Taiwan
Mog001 20303
🇨🇳Kaohsuing CITY, Taiwan
Mog001 20080
🇨🇳Taichung, Taiwan
Mog001 20094
🇨🇳Tainan, Taiwan
Mog001 20304
🇨🇳Taipei City, Taiwan
Mog001 20082
🇨🇳Taiyuan CITY, Taiwan
Mog001 40726
🇹🇷Izmir, Turkey
Mog001 40550
🇹🇷İ̇stanbul, Turkey
Mog001 40648
🇹🇷Samsun, Turkey
Mog001 40725
🇹🇷Sancaktepe, Turkey
Mog001 20319
🇺🇦Kyiv, Ukraine
Mog001 20228
🇺🇦Ternopil, Ukraine
Mog001 40661
🇬🇧Liverpool, United Kingdom
Mog001 40163
🇬🇧Oxford, United Kingdom
Mog001 40123
🇧🇪Anderlecht, Belgium
Mog001 40122
🇧🇪Edegem, Belgium
Mog001 40185
🇧🇪Gent, Belgium
Mog001 60033
🇧🇷Porto Alegre, Brazil
Mog001 40195
🇨🇿Hradec Kralove, Czechia
Mog001 40124
🇨🇿Praha 2, Czechia
Mog001 40721
🇨🇿Teplice, Czechia
Mog001 40657
🇫🇷Bron Cedex, France
Mog001 40422
🇫🇷Caen, France
Mog001 40130
🇫🇷Marseille, France
Mog001 40755
🇫🇷Montpellier, France
Mog001 40170
🇫🇷Strasbourg, France
Mog001 40659
🇩🇪Berlin, Germany
Mog001 40140
🇩🇪Göttingen, Germany
Mog001 40177
🇩🇪Munster, Germany
Mog001 40577
🇩🇪ULM, Germany
Mog001 40146
🇮🇹Pavia, Italy
Mog001 40629
🇮🇹Roma, Italy
Mog001 40646
🇮🇹Verona, Italy
Mog001 20225
🇯🇵Bunkyo-ku, Japan
Mog001 20068
🇯🇵Chiba-shi, Japan
Mog001 20307
🇯🇵Isehara, Japan
Mog001 20143
🇯🇵Kodaira, Japan
Mog001 20223
🇯🇵Koriyama, Japan
Mog001 20224
🇯🇵Sendai, Japan
Mog001 20227
🇯🇵Sendai, Japan
Mog001 20070
🇯🇵Shinjuku-ku, Japan
Mog001 20032
🇯🇵Suita, Japan
Mog001 50297
🇺🇸Scottsdale, Arizona, United States
Mog001 50450
🇺🇸Palo Alto, California, United States
Mog001 50101
🇺🇸Aurora, Colorado, United States
Mog001 50553
🇺🇸Washington, District of Columbia, United States
Mog001 50342
🇺🇸Jacksonville, Florida, United States
Mog001 50308
🇺🇸Tampa, Florida, United States
Mog001 50472
🇺🇸Peoria, Illinois, United States
Mog001 50074
🇺🇸Kansas City, Kansas, United States
Mog001 50552
🇺🇸Baltimore, Maryland, United States
Mog001 50243
🇺🇸Boston, Massachusetts, United States
Mog001 50104
🇺🇸Rochester, Minnesota, United States
Mog001 50571
🇺🇸Cleveland, Ohio, United States
Mog001 50304
🇺🇸Dallas, Texas, United States
Mog001 50568
🇺🇸San Antonio, Texas, United States
Mog001 50473
🇺🇸Salt Lake City, Utah, United States
Mog001 30022
🇦🇺Melbourne, Australia
Mog001 30026
🇦🇺Southport, Australia
Mog001 40756
🇧🇪Bruxelles/brussel, Belgium